13F Holdings
中文EN

NRIX Nurix Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1549595 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY738.8%
TTM net income YoY220.5%
TTM EPS YoY181.8%
Revenue 3-yr CAGR117.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin41.3%
Net margin42.0%
FCF margin52.7%
EBITDA margin42.5%

Returns

ROE44.0%
ROA34.3%
ROIC (approx.)84.5%
Asset turnover0.82x

Leverage & solvency

Liabilities / assets19.0%
Debt / equity0.00x
Current ratio8.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-11-30FY20242024-11-30FY20232023-11-30FY20222022-11-30FY20212021-11-30
Income statement
Revenue$83.98M$54.55M$76.99M$38.63M$29.75M
R&D expense$316.90M$221.63M$189.15M$184.50M$116.43M
SG&A expense$52.74M$45.94M$42.90M$38.00M$31.20M
Operating income-$285.67M-$213.03M-$155.06M-$183.87M-$117.89M
Pretax income-$263.70M-$193.30M-$143.95M-$180.36M-$117.06M
Income tax$760,000$270,000$0$0$131,000
Net income-$264.46M-$193.57M-$143.95M-$180.36M-$117.19M
EBITDA-$276.93M-$203.71M-$147.53M-$178.52M-$115.10M
EPS (basic)-3.05-2.88-2.65-3.71-2.73
EPS (diluted)-3.05-2.88-2.65-3.71-2.73
Dividends declared per share0.000.00———
Weighted avg. shares (diluted)86.67M67.12M54.34M48.61M42.90M
Balance sheet
Cash & equivalents$246.96M$110.90M$54.63M$64.47M$80.51M
Short-term investments———$244.67M$215.21M
Receivables$0$0—$0$6.00M
Current assets$606.82M$619.39M$295.50M$318.45M$311.12M
PP&E, net$22.49M$17.76M$16.81M$17.16M$11.34M
Total assets$688.13M$669.34M$355.60M$416.76M$476.77M
Current liabilities$86.47M$95.85M$86.96M$70.66M$66.26M
Total liabilities$149.39M$142.35M$155.10M$113.06M$134.47M
Shareholders' equity$538.75M$526.99M$200.49M$303.70M$342.30M
Shares outstanding101.81M75.87M48.72M47.17M44.66M
Cash flow statement
Operating cash flow-$249.47M-$172.58M-$81.36M-$159.81M-$84.36M
Capital expenditure$14.00M$9.27M$8.40M$12.24M$5.66M
Free cash flow-$263.47M-$181.86M-$89.77M-$172.05M-$90.03M
Investing cash flow$147.85M-$257.71M$68.30M$27.20M-$108.25M
Financing cash flow$238.64M$485.67M$3.22M$117.19M$153.88M
Depreciation & amortization$8.74M$9.32M$7.53M$5.35M$2.79M
Stock-based compensation$37.97M$33.93M$33.67M$28.13M$15.80M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.